Persistent Sexual Dysfunction and SSRIs: Myth or Reality? (authors: Figueiredo, Freitas, Ferreira, 2022)
Posted: Thu Oct 06, 2022 6:08 pm
Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?
Carlos José Marinho Figueiredo - Corresponding Author
Unidade de Saúde Familiar Aqueduto, Vila do Conde, Portugal.
Carlos M. Figueiredo [carlos.figueiredo.1993@gmail.com]
Rua Norton de Matos, 300, 4760-157 Vila Nova de Famalicão, Portugal
https://orcid.org/0000-0002-5064-6251
José Diogo Silva Castro Faria Freitas
Unidade de Saúde Familiar Navegantes, Vila do Conde, Portugal.
Maria do Céu Ferreira
Serviço de Psiquiatria, Centro Hospitalar Póvoa de Varzim/ Vila do Conde, Póvoa de Varzim, Portugal.
ABSTRACT
Selective serotonin reuptake inhibitors antidepressants are psychopharmaceuticals frequently used in clinical practice in the fields of General Practice and Psychiatry for the treatment of depressive and anxiety disorders. The high prescription of this class of antidepressants results from their profile of efficacy, safety and tolerability.
It is clinically consensual that this pharmacological class can interfere with the various phases of the sexual response during antidepressant treatment. However, more and more cases have been reported in the literature, in which sexual dysfunction is not reversible after discontinuation of the drug, configuring a new persistent clinical entity, whose pathophysiological substrate is currently under intense scientific investigation. Reviewing the recent published literature in this matter and raising awareness of physicians about this new entity reveals itself as a priority with potential implications, particularly on the approach of psychiatric pathologies so prevalent in the current society.
Keywords: Serotonin Uptake Inhibitors/adverse effect; Sexual Dysfunction, Physiological/chemically induced
Marinho Figueiredo CJ, Silva Castro Faria Freitas JD, Ferreira M do C. Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?. Gaz Med [Internet]. 2022 Sep. 1 [cited 2022 Oct. 6];9(3):230-9. Available from: http://www.gazetamedica.com/index.php/g ... e/view/572
Issue
NUMBER 3 · VOLUME 9 · JULY/SEPTEMBER 2022
Full text (Portuguese):
https://www.researchgate.net/publicatio ... or_Reality
Carlos José Marinho Figueiredo - Corresponding Author
Unidade de Saúde Familiar Aqueduto, Vila do Conde, Portugal.
Carlos M. Figueiredo [carlos.figueiredo.1993@gmail.com]
Rua Norton de Matos, 300, 4760-157 Vila Nova de Famalicão, Portugal
https://orcid.org/0000-0002-5064-6251
José Diogo Silva Castro Faria Freitas
Unidade de Saúde Familiar Navegantes, Vila do Conde, Portugal.
Maria do Céu Ferreira
Serviço de Psiquiatria, Centro Hospitalar Póvoa de Varzim/ Vila do Conde, Póvoa de Varzim, Portugal.
ABSTRACT
Selective serotonin reuptake inhibitors antidepressants are psychopharmaceuticals frequently used in clinical practice in the fields of General Practice and Psychiatry for the treatment of depressive and anxiety disorders. The high prescription of this class of antidepressants results from their profile of efficacy, safety and tolerability.
It is clinically consensual that this pharmacological class can interfere with the various phases of the sexual response during antidepressant treatment. However, more and more cases have been reported in the literature, in which sexual dysfunction is not reversible after discontinuation of the drug, configuring a new persistent clinical entity, whose pathophysiological substrate is currently under intense scientific investigation. Reviewing the recent published literature in this matter and raising awareness of physicians about this new entity reveals itself as a priority with potential implications, particularly on the approach of psychiatric pathologies so prevalent in the current society.
Keywords: Serotonin Uptake Inhibitors/adverse effect; Sexual Dysfunction, Physiological/chemically induced
Marinho Figueiredo CJ, Silva Castro Faria Freitas JD, Ferreira M do C. Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?. Gaz Med [Internet]. 2022 Sep. 1 [cited 2022 Oct. 6];9(3):230-9. Available from: http://www.gazetamedica.com/index.php/g ... e/view/572
Issue
NUMBER 3 · VOLUME 9 · JULY/SEPTEMBER 2022
Full text (Portuguese):
https://www.researchgate.net/publicatio ... or_Reality